Published in: OncoImmunology
Authors: Aki Furusawa, Ryuhei Okada, Fuyuki Inagaki, Hiroaki Wakiyama, Takuya Kato, Hideyuki Furumoto, Hiroshi Fukushima, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi
The study aimed to develop photoimmunotherapy for pigmented melanoma, which can challenging indication since the pigment could absorb light and make treatment ineffective. In vitro & in vivo studies with ML7710 laser compared PIT against pigmented and non-pigmented melanoma and found no differences. CD29 targeted PIT was more effective than CD44 targeted PIT, relating to expression of CD44 on the surface of key immune cells like T cells and dendritic cells that have role in augmenting the therapeutic effects of PIT. Addition of CTLA4 immune checkpoint inhibitor to CD29-PIT further increased the treatment efficacy.
